Haemonetics Corporation $HAE Shares Sold by Boston Trust Walden Corp

Boston Trust Walden Corp lowered its stake in shares of Haemonetics Corporation (NYSE:HAE) by 13.6% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 501,885 shares of the medical instruments supplier’s stock after selling 78,765 shares during the period. Boston Trust Walden Corp owned 1.08% of Haemonetics worth $28,286,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. AQR Capital Management LLC grew its holdings in Haemonetics by 48.6% in the fourth quarter. AQR Capital Management LLC now owns 3,163,104 shares of the medical instruments supplier’s stock valued at $253,523,000 after purchasing an additional 1,034,226 shares during the period. Arrowstreet Capital Limited Partnership raised its stake in Haemonetics by 994.7% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,380,102 shares of the medical instruments supplier’s stock worth $110,615,000 after purchasing an additional 1,254,035 shares during the period. North Peak Capital Management LLC boosted its holdings in shares of Haemonetics by 204.4% in the 4th quarter. North Peak Capital Management LLC now owns 1,102,992 shares of the medical instruments supplier’s stock valued at $88,405,000 after purchasing an additional 740,626 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Haemonetics by 2.5% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,099,519 shares of the medical instruments supplier’s stock valued at $53,587,000 after purchasing an additional 26,763 shares during the last quarter. Finally, Fort Washington Investment Advisors Inc. OH grew its stake in shares of Haemonetics by 17.3% during the 1st quarter. Fort Washington Investment Advisors Inc. OH now owns 841,017 shares of the medical instruments supplier’s stock valued at $47,400,000 after buying an additional 124,020 shares during the period. 99.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Robert W. Baird set a $67.00 price objective on shares of Haemonetics in a research report on Friday, May 8th. Weiss Ratings upgraded Haemonetics from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, June 25th. Citigroup increased their target price on Haemonetics from $64.00 to $70.00 and gave the stock a “neutral” rating in a report on Thursday, May 28th. Barrington Research decreased their target price on Haemonetics from $94.00 to $89.00 and set an “outperform” rating for the company in a research report on Tuesday, May 12th. Finally, BTIG Research reiterated a “buy” rating and issued a $84.00 price target on shares of Haemonetics in a report on Friday, June 26th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $78.33.

Haemonetics Stock Down 0.2%

Shares of Haemonetics stock opened at $74.93 on Friday. The firm has a market cap of $3.41 billion, a price-to-earnings ratio of 37.09, a P/E/G ratio of 1.51 and a beta of 0.52. Haemonetics Corporation has a 52-week low of $47.31 and a 52-week high of $87.32. The stock has a 50-day simple moving average of $66.82 and a 200-day simple moving average of $66.55. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.95 and a quick ratio of 1.87.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.01. Haemonetics had a return on equity of 27.30% and a net margin of 7.29%.The company had revenue of $346.35 million during the quarter, compared to analysts’ expectations of $336.83 million. During the same quarter in the previous year, the firm earned $1.24 earnings per share. The business’s quarterly revenue was up 4.8% compared to the same quarter last year. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. On average, equities research analysts expect that Haemonetics Corporation will post 5.22 earnings per share for the current fiscal year.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.